Startup · $17.5m raised
Sydney, NSW
Every investor coverage indicates participated in a round Elastagen Pty Ltd raised.
| Investor | Rounds | Invested |
|---|---|---|
| AMOREPACIFIC Ventures | Series B | - |
| ATP Innovations | Series B | - |
| Brandon Capital | Series B | - |
| GBS Ventures | Series B | - |
| Korea Investment Partners | Series B | - |
| NSW Government | Grant | - |
| NSW Health Medical Devices Fund | Grant | - |
| the NSW state government | Grant | - |
| Wellcome Trust | Series B | - |
The transaction that ended Elastagen Pty Ltd's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Allergan plc | Acquisition | 7 Feb 2018 | $350m | Startup Daily (Thu 3 Aug 2023), Startup Daily (Mon 14 Sep 2020), Startup Daily (Thu 2 May 2019), Brandon BioCatalyst portfolio, Brandon Capital portfolio, GBS Ventures (Fri 28 Sep 2018), GBS Ventures (Wed 7 Feb 2018) |
Companies Elastagen Pty Ltd acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Rob Daniels | CEO | Startup Daily |
| Robert Daniels | CEO | GBS Ventures (Wed 7 Feb 2018), GBS Ventures (Tue 21 Jun 2016), GBS Ventures (Tue 12 Jan 2016), GBS Ventures (Tue 20 Sep 2011) |
| Sangwoo Lee | Board of Directors | GBS Ventures |
Stories naming Elastagen Pty Ltd. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Anniversary profile of incubator Cicada Innovations' two decades, telling portfolio biotech Elastagen's story: its tropoelastin work, Series A backing, a government grant, and its 2018 sale to Allergan.
Also GBS Ventures·GBS Ventures
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily
Sydney-based tropoelastin biotech Elastagen agreed to an Allergan takeover offering US$95 million upfront plus contingent payments; the GBS Ventures-backed company previously drew MDF and federal grant funding.
Also GBS Ventures·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Startup Daily·Startup Daily·Startup Daily
NSW Government's 2016 Medical Devices Fund awarded $8.6 million to four medtech companies, Elastagen getting $4 million; earlier winners Saluda Medical and Atomo Diagnostics also feature, the latter having lately drawn Gates Foundation money.
Cell Innovation Partners invested A$1 million in Sydney biotech Elastagen within a second close of its A$14 million Series B, with AMOREPACIFIC Ventures, Korea Investment Partners and the Wellcome Trust also joining the round.
Sydney clinical-stage medical company Elastagen closed a A$13 million Series B, adding KIP, AMOREPACIFIC Ventures and Wellcome Trust to its existing backers; KIP's Sangwoo Lee joined the board.
Two medical technology companies, Elastagen and Endoluminal Sciences, together received $4.5 million from the NSW Government's Medical Devices Fund, a competitive program backing local medical device development and commercialisation.
Sydney medical device company Elastagen completed a first-in-human study of its synthetic elastin skin products and plans two further trials, targeting a European launch in early 2013.